• Skip to primary navigation
  • Skip to main content

Highlights:

Read more
  • Careers
  • Support
  • Contact Us
AMRA Medical

AMRA Medical

Insights Within

  • Focus Areas
  • Our Services

      Research Services

      Unlock breakthroughs and power your clinical trials by implementing our research biomarkers to maximize your trial’s success and de-risk the drug development lifecycle. Read more

      Imaging Biomarkers
      MRI-based fat and muscle analysis measures for drug development teams.
      Insights Biomarkers
      Advanced analysis—descriptive, functionally-relevant fat and muscle assessment methodologies.

      Clinical Services

      Our clinical biomarkers provide your practice with easy-to-understand insights that are personalized and informative for each and every patient. Read more

      AMRA® BCP Scan
      Understand your patient’s fat and muscle composition using MRI-based measurements within health and wellness.
      AMRA® MAsS Scan
      Learn more about your patient’s muscle quality using our Muscle Assessment Score

      Services Based on Knowledge

      Read publications, insights articles and view insightful webinars.

      Insights Article

      Revealing the true impact of drug therapies for metabolic diseases through weight-invariant fat distribution assessment using AMRA’s Z-Scores

      Publication

      Evaluating the prevalence and severity of metabolic dysfunction-associated steatotic liver disease in patients with type 2 diabetes mellitus in primary care

      Explore more at our Knowledge Hub →

  • Science

      Science

      AMRA is on the forefront of precision medicine—providing body composition and medical insights driven by our digital health platform, team of experts, and ability to develop MRI biomarkers suitable for both clinical practice and research.

      Read more →

      What We Do
      We analyze MRI to classify and quantify muscle and fat with unprecedented accuracy and precision.
      How We Do It
      Our process of imaging technology and a massive reference database for fat and muscle composition.
      Why It Matters
      Our data guide decision-making—impacting your clinical trials and patient’s lives.
      Technology
      We’ve developed a patented, automated method for classifying and quantifying fat and muscle groups.
  • Knowledge Hub
  • About

      Company

      Our Story
      Read the story of AMRA—how it all started in academic research and grew into a science-driven partner helping researchers see what truly matters.
      Our Team
      At AMRA Medical, our work is powered by passionate people committed to advancing science and clinical outcomes. If you’re driven by curiosity, innovation, and impact, we’d love to meet you.
      Careers
      With careers at AMRA, you’ll have access to tools, learning opportunities, and guidance that help you progress and shape your career step by step.
      News
      Browse the latest updates from AMRA, including company news and press releases, recent research highlights, and stories showcasing ground-breaking health informatics innovation.
      Events
      Explore our event schedule below to see where we’re engaging with researchers, clinicians, industry partners, and other key stakeholders in order to drive progress.
      Media Kit
      AMRA’s Media Kit provides access to essential materials about AMRA, including relevant company information and useful brand assets.

      About AMRA

      AMRA Medical is a health informatics company at the forefront of medical imaging and precision medicine. The company has developed a new global standard in body composition analysis, delivering multiple fat and muscle biomarkers with unrivaled accuracy and precision – all from a rapid whole-body MRI scan.

      Read more →

  • Get Started

Large-scale body composition study reveals link between specific fat distributions and metabolic diseases

May 22, 2018
  • Twitter
  • Facebook
  • LinkedIn

New study in Obesity reveals metabolic phenotypes described by skewed body fat distributions

Linköping, Sweden [May 22, 2018]: Specific patterns of fat distribution are linked to the presence of Coronary Heart Disease (CHD) and Type 2 Diabetes (T2D), according to a new study published in Obesity.1 AMRA, the international leader in body composition analysis, today announced the results of a body composition study of over 6,000 subjects, stressing the need to measure and investigate several fat compartments in order to understand and develop treatments for multiple metabolic diseases. The new findings go far beyond what can be described by sex, age, lifestyle, BMI, or a single fat compartment, and have the potential to strongly impact how metabolic conditions will be prevented and managed in the future.

The Obesity study was co-authored in collaboration between AMRA, Pfizer, Westminster University and Linköping University. The 6,000 subjects analyzed are part of the UK Biobank Imaging Study, a major national and international health resource. In 2015, UK Biobank announced that AMRA would perform the automated analysis of MRI images for precise fat and muscle measurements. AMRA has now developed the technique of body composition profiling, which allows for precise analysis of multiple variables to describe the complex associations and interactions between fat distribution, muscle volumes, and metabolic status.

Regardless of normal, overweight, or obese BMI class, AMRA’s body composition profiling of the subjects revealed a number of skewed fat distribution patterns, or phenotypes, that cannot be described when looking at a single fat or muscle measurement. These phenotypes are associated with different metabolic disease profiles: some exhibit no metabolic disease, while others exhibit CHD, T2D, or the co-morbidity of the two. Specifically, higher visceral fat and muscle fat was associated with CHD and T2D (p<0.001) while higher liver fat was associated with T2D (p<0.001) and lower liver fat with CHD (p<0.05). Lower visceral fat and muscle fat was also associated with metabolic health (p<0.001), whereas liver fat was non-significant. Associations remained significant when adjusting for sex, age, BMI, alcohol, smoking, and physical activity.

Dr Olof Dahlqvist Leinhard, senior author of the study, commented, “It has been known for some time that there are fat distributions that are disadvantageous from a health perspective. Today, new techniques provide high accuracy and precision, enabling in-depth analyses of the clinical importance of body composition at a large scale. What’s exciting is that, by using a multivariable approach and an intuitive visualization of body composition, we’ve been able to identify a wide range of body composition profiles that could provide the link to increased risk of metabolic diseases.”

Tommy Johansson, Chief Executive Officer of AMRA, added, “These ground-breaking results allow a glimpse into the future where precision diagnostics will provide the backbone to personalized medicine. By better understanding of muscle and fat volumes, and where fat is located in the body, we hope to help redefine disease risk and suitability for treatment. Our vision is that, in the future, our research and technology will be used to assist in the improved prevention, diagnosis, and treatment of a wide range of diseases.”

Today a quarter of the world’s adults have Metabolic Syndrome – a cluster of factors that increase the risk of several chronic diseases, such as heart disease, cancer, stroke, liver disease and diabetes.2 Obesity, CVD and T2D are growing pandemics and leading causes of early death globally, presenting some of the greatest challenges to patients and healthcare systems worldwide.3,4,5,6

 

-ENDS-

 

Study detail

The first 6,021 participants from the UK Biobank imaging sub-study – mean age 62.3±7.5 years, and BMI 26.7±4.4 kg/m2 – were scanned using a Rapid MRI protocol providing a water and fat separated volumetric dataset covering neck to knees, and a single slice for proton density fat fraction (PDFF) assessment in the liver. For body composition, acquired image data were analyzed for visceral adipose tissue, abdominal subcutaneous adipose tissue, thigh muscle volume, muscle fat infiltration in the anterior thighs, and liver PDFF. Briefly, the image analysis comprised of (1) image calibration, (2) fusion of image stacks, (3) image segmentation, (4) quantification of fat and muscle volumes7,8,9,10,11 and manual quality control by an analysis engineer.

Diagnosis information was gathered through in-patient electronic healthcare records and via touchscreen questionnaires followed by interviews performed by trained nurses. For CHD and T2D, two matched control groups were stratified matched on (1) sex and age, and (2) sex, age, and BMI. Participants were considered metabolic disease free if they did not report any conditions considered to be serious enough to represent metabolically-focused health concerns (e.g. cardiovascular and metabolic diseases, severe chronic conditions, neurological diseases, and cancers).12

The study was carried out as a collaboration between AMRA Medical, Pfizer, Westminster University and Linköping University. Funding support was provided by Pfizer.

 

About AMRA

AMRA is the first in the world to transform images from a rapid, Rapid whole body MRI scan into precise, 3D-volumetric fat and muscle measurements. AMRA’s cloud-based analysis service offers precise, automated insights that have far-reaching implications for the pharmaceutical industry, academic R&D and, soon, clinical practice. AMRA was founded in 2010 as a spin-off of the Center for Medical Image Science and Visualization (CMIV), the Department of Biomedical Engineering (IMT) and the Department of Medicine and Health (IMH) at Linköping University, Sweden. For more information, visit www.amramedical.com.

AMRA Medical
Rosemary Shull
SVP Global Business Development & Marketing
rosemary.shull@amramedical.com

 

About UK Biobank

UK Biobank is a major national and international health resource with the aim of improving the prevention, diagnosis and treatment of a wide range of serious and life-threatening illnesses – including cancer, heart diseases, stroke, diabetes, arthritis, eye disorders, depression and forms of dementia. UK Biobank recruited 500,000 people aged between 40–69 years in 2006–2010 from across the country, when they provided lots of information about their health and well-being and donated samples of blood and urine for long-term storage and analysis, including genetic information. The project has permission to follow participants’ health through medical records. UK Biobank has also embarked on a major project to MRI scan the vital internal organs and body composition of 100,000 participants. Over many years, these detailed data will build a powerful resource to help scientists discover why some people develop particular diseases and others do not, and to suggest new ways of preventing and treating them.

UK Biobank
Andrew Trehearne
Head of Communications
andrew.trehearne@ukbiobank.ac.uk

 

1 http://onlinelibrary.wiley.com/doi/10.1002/oby.22210

2 Worldwide Definition of the Metabolic Syndrome, International Diabetes Federation (IDF)

3 Chang S-H, et al. JAMA Surg 2014;149:275–87

4 IDF diabetes atlas. 2015. Available at: http://www.diabetesatlas.org [last accessed 06.10.16]

5 Branca F, et al. The Challenge of Obesity in the WHO European Region and the Strategies for Response: Summary. 2007

6 Klein S, et al. Obesity (Silver Spring) 2011;19:581–7

7 West J, Dahlqvist Leinhard O, Romu T, et al. Feasibility of MR-based Body Composition Analysis in Large Scale Population Studies. PLoS ONE 2016;11(9)

8 Borga M, Thomas EL, Romu T, et al. Validation of a Fast Method for Quantification of Intra-abdominal and Subcutaneous Adipose Tissue for Large Scale Human Studies. NMR Biomed 2015;28(12):1747–53

9 OD Leinhard, A Johansson, J Rydell, et al.  Quantitative Abdominal Fat Estimation Using MRI Pattern Recognition. In: Proceedings of the 19th International Conference on Pattern Recognition (ICPR) 08–11 Dec, 2008; Tampa, FL

10 Karlsson A, Rosander J, Romu T, et al. Automatic and Quantitative Assessment of Regional Muscle Volume by Multi-Atlas Segmentation Using Whole-Body Water-Fat MRI. JMRI 2015;41(6):1558–69

11 West J, Romu T, Thorell S, et al.. Precision of MRI-based body composition measurements of postmenopausal women. PLoS One 2018;13(2):e0192495

12 UK Biobank Data Showcase. Available at: http://biobank.ctsu.ox.ac.uk/crystal/ [last accessed 16.11.17]

 

All posts
  • Twitter
  • Facebook
  • LinkedIn

Get all the latest updates from AMRA

Valuable insights and exclusive updates from AMRA Medical on the MRI-based fat and muscle analytics shaping research and clinical care, delivered straight to your inbox.

Footer icon
  • Focus Areas
    • Disease Research Areas
    • Health & Wellness
    • Sectors
  • Our Services
    • Research Services
    • Clinical Services
  • About Us
    • Our Team
    • Careers
    • News
    • Media Kit
  • Knowledge Hub
    • Insights Articles
    • Webinar
    • Publications
© 2026 AMRA Medical AB
  • Data Privacy Policy
  • Cookie Policy
AMRA Medical
Manage Cookie Consent
To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Functional Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes. The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
  • Manage options
  • Manage services
  • Manage {vendor_count} vendors
  • Read more about these purposes
View preferences
  • {title}
  • {title}
  • {title}
AMRA Medical
Manage Cookie Consent
To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Functional Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes. The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
  • Manage options
  • Manage services
  • Manage {vendor_count} vendors
  • Read more about these purposes
View preferences
  • {title}
  • {title}
  • {title}